Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230424 · ClinicalTrials.gov registry record · Phase 4
Effect of Steroid Injections in a Knee With Osteoarthritis
A Phase 4 study of Osteoarthritis (OA) of the Knee, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT01230424: Completed Phase 4 study of Osteoarthritis (OA) of the Knee, sponsored by Tufts Medical Center.
NCT01230424 is a Phase 4 study of Osteoarthritis (OA) of the Knee that has completed, run by Tufts Medical Center. The registered enrollment target is 140 participants, below the 1,396-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01230424, a Phase 4 study of Osteoarthritis (OA) of the Knee, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
A steroid (triamcinolone) 40 mg will be compared to placebo in a randomized placebo-controlled clinical trial testing the effect of this steroid versus placebo given into the study knee joint that has osteoarthritis (OA). The knee injection will be given once every 12 weeks over two years for a total of eight knee injections. How well each participant tolerates each injection and all the injections over time will be assessed. The safety of getting a knee injection every 12 weeks will be assessed by collecting reported adverse effects, knee examinations, and clinical laboratory tests. Participants will complete questionnaires, X-ray, MRIs, and bone density tests as part of this study.
Primary Outcome
Mean cartilage thickness was measured on knee MRI (Philips Achieva X-Series 3.0 Tesla scanner). Missing data were imputed.
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG 0.9% Sodium Chloride Injection as Placebo
Study Locations (2)
Massachusetts
- Tufts Medical Center / Division of Rheumatology - Boston
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
What the finished NCT01230424 record still lists
NCT01230424 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,396-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Osteoarthritis (OA) of the Knee appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT01230424 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01230424 about?
NCT01230424 is a clinical study titled "Effect of Steroid Injections in a Knee With Osteoarthritis". A steroid (triamcinolone) 40 mg will be compared to placebo in a randomized placebo-controlled clinical trial testing the effect of this steroid versus placebo given into the study knee joint that has osteoarthritis (OA). The knee injection will be given once every 12 weeks over two years for a tota...
What is the current status of trial NCT01230424?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2011-03. Estimated completion is 2015-01.
What conditions does trial NCT01230424 study?
This clinical trial studies the following conditions: Osteoarthritis (OA) of the Knee.
What interventions are being tested in trial NCT01230424?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), 0.9% Sodium Chloride Injection as Placebo (DRUG).
Who is sponsoring clinical trial NCT01230424?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01230424 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis (OA) of the Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01230424's enrollment target sits among peer trials
140 6th of 8 higher than 3 of 8 other Osteoarthritis (OA) of the Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis (OA) of the Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
RECRUITING · Phase 4
-
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Platelet Rich Plasma for Musculoskeletal Conditions
RECRUITING · NA
-
Native Alignment in the Setting of an Arthritic Knee in Total Knee Arthroplasty
RECRUITING · NA
-
Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy
RECRUITING · NA
-
Injectable Cold Energy Therapy FOR THE Management OF Chronic Pain Associated With Osteoarthritis OF THE Knee
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia